Sunshine Biopharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.4M
- Price
- $0.8758
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.37%
- Volume
- 94.7K
About
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Quick stats
Shares outstanding3.9M
Computed float3.8M
Float / shares96.7%
Cash runway (months)42.4
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001402328
AI Summary
AI-generated1/20
standardbullishclinical trial
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Sunshine Biopharma has advanced its lead Coronavirus drug candidate, a PLpro protease inhibitor, into IND-enabling studies, moving the asset out of pure discovery and toward a potential investigational new drug filing.
The preclinical package includes nanomolar potency against the viral protease across SARS-CoV-2 variants of concern, high oral bioavailability in mice, rats and dogs, preferential lung enrichment, and dose-dependent suppression of pulmonary viral replication in SARS-CoV-2-infected K18-hACE2 mice.
Management framed the nomination as strategically significant and claims a competitive position in next-generation coronavirus therapeutics, but no IND filing date, study budget, or human trial timeline was disclosed.
Beyond the pipeline, the company's commercial base remains 60 generic prescription drugs on the market in Canada with approximately 12 additional launches planned for the remainder of 2026.
Red flags
- Preclinical-stage only: IND not yet filed and no timeline or cost disclosed for IND-enabling studies
- Efficacy data limited to animal models (K18-hACE2 mice), no human data
- Micro-cap biotech with costly IND-enabling work ahead -- funding and dilution risk unaddressed in release